Grants for Public and State controlled institutions of higher education - Federal

This funding opportunity provides financial support for research projects that aim to improve the inclusion, independence, and quality of life for individuals with disabilities, particularly focusing on underserved populations and critical issues affecting these communities.

This funding opportunity provides financial support to state and local governments, Tribal organizations, educational institutions, and non-profits to improve outdoor recreation access and promote environmental stewardship in Idaho.

The Study of the U.S. Branch (ECA/A/E/USS), Office of Academic Exchange Programs, Bureau of Educational and Cultural Affairs (ECA), invites proposal submissions from U.S. public and private academic and cultural institutions, exchange-of-persons, and other not-for-profit organizations meeting the provisions described in Internal Revenue Code section 26 USC 501(c)(3) (see section C. Eligibility Information) for the design and implementation of four (4) Institutes for the Study of the U.S., Madeleine K. Albright Young Women Leaders Program (Albright Young Women Leaders Program). Four Institutes will take place over five weeks in summer 2025. Each Institute will focus on a theme that reflects U.S. foreign policy priorities. The themes selected for these Institutes are: Civic Engagement, Economic Empowerment, Environmental Issues, and Public Policy. See details in section A.3. Program Specific Guidelines, in the Notice of Funding Opportunity. The Albright Young Women Leaders Program will provide multinational groups of undergraduate female students with a deeper understanding of U.S. society, culture, values, and institutions while simultaneously developing their leadership skills. Each Institute will be organized for a group of 20 foreign undergraduate women for a total of 80 participants in four concurrent Institutes. Institutes will be approximately five weeks in duration and will include an approximately four-week academic residency at a U.S. academic institution and an approximately one-week integrated study tour that will expose the foreign undergraduate students to a community (or multiple communities) representing a culture and/or region distinct from that of their academic residency. A convening event will bring participants together from all four Institutes for networking and exploration of program themes. Please see the full announcement for additional information.

UPDATED NOTICE - PLEASE READ: April 6, 2023 EDA is excited to announce the launch of its new grants management platform: the Economic Development Grants Experience (EDGE). EDGE was developed to streamline the application and grants management process by implementing a single platform with increased transparency, improved user experience, higher data quality, and more efficiency throughout the entire grant lifecycle. As of April 6th, 2023, applications can no longer be submitted on Grants.gov, and will ONLY be accepted through EDGE. To apply in EDGE, please go to: sfgrants.eda.gov. More information on how to apply is provided in the full NOFO. PARTNERSHIP PLANNING program instructions: Please note that applicants will be invited to submit applications through EDGE for the Partnership Planning program. For more information, please reach out to your EDA point of contact. Program Description: EDA makes planning and local technical assistance investments to support economic development, foster job creation, and attract private investment in economically distressed areas of the United States. Under the Planning program, EDA makes Partnership Planning, Short-Term Planning, and State Planning awards to eligible recipients to create and implement regional economic development plans designed to build capacity and guide the economic prosperity and resiliency of an area or region. More specifically, EDA makes Partnership Planning investments to designated planning organizations (i.e., District Organizations) serving EDA-designated Economic Development Districts and to Indian Tribes to facilitate the development, implementation, revision, or replacement of Comprehensive Economic Development Strategies (CEDS), which articulate and prioritize the strategic economic goals of recipients respective regions. EDA also makes Short-Term and State Planning awards for economic development planning activities that guide the eventual creation and retention of high-quality jobs, particularly for the unemployed and underemployed in the Nations most economically distressed regions. Under the Local Technical Assistance program, EDA makes awards to strengthen the capacity of local or State organizations, institutions of higher education, and other eligible entities to undertake and promote effective economic development programs through projects such as feasibility studies, impact analyses, disaster resiliency plans, and project planning. **Please note: While the published Notice of Funding Opportunity (available under "Related Documents") states that the ED900A form and the SF424B form are both required for a complete application, these forms are no longer required and have therefore been removed from the package template.

The "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that focus on the development of innovative technologies for analyzing molecular or cellular aspects of cancer, with the goal of improving cancer biology research, early detection, diagnosis, treatment, control, epidemiology, and addressing health disparities related to cancer.

This funding opportunity provides financial support for innovative projects that develop and scale up biofuel technologies, particularly for transportation sectors that are hard to electrify, with a focus on reducing greenhouse gas emissions and promoting environmental justice.

The National Institutes of Health (NIH) has announced a funding opportunity titled Co-infection and Cancer (R01 Clinical Trial Not Allowed) under Funding Opportunity Number PAR-25-082. This initiative, led by the National Cancer Institute (NCI), is aimed at advancing research into the roles of co-infection in cancer development and progression. Co-infection is defined as the occurrence of two or more infections, whether simultaneous or sequential, involving pathogens or non-pathogenic agents, including viruses, bacteria, and parasites. The goal of this program is to explore how these co-infections contribute to cancer risk and progression and identify potential strategies for cancer prevention and treatment. The program encourages investigations that focus on co-infections with known oncogenic agents, excluding human immunodeficiency virus (HIV), and seeks studies that can lead to new opportunities in cancer treatment and prevention. In addition to pathogenic agents, research that includes the role of non-pathogenic agents, such as those in the microbiome, will be considered responsive. The program supports projects that delve into uncharted areas of co-infection and cancer, with an emphasis on mechanistic and epidemiologic research that could have practical implications for cancer control. Applicants are encouraged to focus on differences in cancer susceptibility, progression, and survival among diverse populations, including those that are racially or ethnically diverse, as well as medically underserved communities. International collaborations are also supported, particularly for studies in low- and middle-income countries where infection-associated cancers are more prevalent. The first submission date is January 5, 2025, with application due dates beginning on February 5, 2025. Budgets are not limited but must align with the scope of the project, and the maximum project period is five years. Applications must be submitted electronically through NIH's ASSIST system or Grants.gov. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and foreign entities. The program seeks to support well-developed research projects backed by preliminary data. Studies that focus solely on co-infection with HIV or involve only a single pathogen will not be considered responsive. Evaluation criteria include the scientific merit of the project, innovation, and feasibility, as well as the expertise of the research team. This funding opportunity offers a unique chance to explore how co-infections contribute to cancer and potentially uncover new strategies for prevention and treatment across diverse populations.

This funding opportunity supports research that provides critical data to help the FDA regulate tobacco products, targeting a wide range of organizations, including nonprofits, educational institutions, and community groups, to improve public health outcomes related to tobacco use.

This funding opportunity is designed for research partners in the Great Lakes-Northern Forest region to study and develop strategies for controlling the invasive Grass Carp population in Lake Erie and its tributaries.

This funding opportunity supports innovative researchers in the U.S. who are tackling significant challenges in diabetes, metabolic diseases, digestive disorders, and nutrition, with the goal of advancing groundbreaking scientific understanding and treatment.

This grant provides funding for research initiatives that enhance the coordination of human services to improve the well-being of low-income families and those from underserved communities over a five-year period.

This funding opportunity provides $5 million to support the deployment and commercialization of innovative technologies in public transportation, aimed at federal, state, local, and tribal governments, as well as public transit providers and educational institutions.

This funding opportunity supports postdoctoral researchers from underrepresented groups in cancer research as they transition to independent faculty positions, providing salary and research funding to help establish their own research programs.

The National Aeronautics and Space Administration (NASA) Headquarters has released a solicitation, titled Early Stage Innovations (ESI), as an appendix to the Space Technology Mission Directorate (STMD) umbrella NASA Research Announcement (NRA) titled "Space Technology Research, Development, Demonstration, and Infusion 2024 (SpaceTech REDDI 2024), on April 4, 2024. The ESI solicitation is available by opening the NSPIRES homepage at https://nspires.nasaprs.com/, selecting Open under "Solicitations," and searching "Early Stage Innovations (ESI24)" under Keywords. The Space Technology Research Grants (STRG) Program within STMD seeks proposals from accredited U.S. universities to develop unique, disruptive, or transformational space technologies that have the potential to lead to dramatic improvements at the system level performance, weight, cost, reliability, operational simplicity, or other figures of merit associated with spaceflight hardware or missions. The projected impact at the system level must be substantial and clearly identified. Only accredited U.S. universities are eligible to submit proposals. Teaming is permitted see solicitation for complete eligibility requirements as well as teaming restrictions. A Principal Investigator (see solicitation for restrictions) or Co-Investigator may participate in no more than two proposals in response to this solicitation. NASA encourages submission of ESI proposals on behalf of tenure-track or tenured faculty members at all U.S. universities and especially encourages proposals submitted on behalf of and/or that include as team members women, members of underrepresented minority groups, and persons with disabilities. The solicitation exclusively seeks proposals that are responsive to one of the following two topics: Topic 1 Computational Materials Engineering for Lunar Metals Welding Topic 2 Passive Lunar Dust Control through Advanced Materials and Surface Engineering NASA anticipates addressing other topics in future ESI Appendix releases. The financial and programmatic support for ESI comes from the Space Technology Research Grants Program within the Space Technology Mission Directorate. Awards are planned to start in January 2025. NASA plans to make approximately 6 awards as a result of this ESI solicitation, subject to the receipt of meritorious proposals. The actual number of awards will depend on the quality of the proposals received; NASA reserves the right to make no awards under this solicitation. STMD is strongly committed to ensuring that proposal review is performed in an equitable and fair manner that reduces the impacts of any unconscious biases. To this end, this Appendix will employ a Dual-Anonymous Peer Review (DAPR) process to evaluate proposals. Using DAPR, not only are proposers not told the identities of the reviewers, but the identities of the proposers (personnel and organization names) will not be shared with the reviewers until after the technical review of all anonymized proposals has been completed. All proposals must be submitted electronically through NSPIRES by an authorized organizational representative. Notices of Intent (strongly encouraged) are due by May 9, 2024, with proposals due on or before June 6, 2024, 5 pm Eastern. Detailed submission instructions and due dates are provided in the solicitation. Potential proposers and their proposing organizations are urged to familiarize themselves with the submission system, ensure they are registered in NSPIRES, and submit the required proposal materials well in advance of the deadline. All technical and programmatic comments and questions may be addressed by email to the Space Technology Research Grants Program Executive, at [email protected]. Responses to inquiries will be answered by email and may also be included in the Frequently Asked Questions (FAQ) documents located on the NSPIRES page associated with the solicitation; anonymity of persons/institutions who submit questions will be preserved.

Questions regarding this Funding Opportunity Announcement (FOA) Forecast may be emailed to [email protected]; however, please note there is limited information that may be shared with the public, as this FOA is currently under development. We encourage prospective applicants and interested parties to use the Grants.gov subscription option to register for future updates provided for this particular FOA.

This funding opportunity supports innovative clinical research to explore the brain mechanisms behind substance use disorders, targeting a wide range of researchers and institutions dedicated to addressing addiction challenges.

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.

This funding opportunity provides financial support to cultural institutions like museums and libraries to implement environmentally sustainable strategies for preserving their collections and improving storage conditions.

This funding opportunity provides financial support for researchers to analyze and integrate existing data to better understand cancer risk, prevention, and treatment outcomes, particularly focusing on innovative methodologies and addressing health disparities.

This ISO seeks solution summaries and proposal submissions for projects that fall within the general scope of the ARPA-H Health Science Futures (HSF) mission office. HSF expands what is technically possible by developing approaches that will remove the scientific and technological limitations that stymie progress towards the healthcare of the future. HSF supports cutting-edge, often disease-agnostic research programs that have the potential for translational real-world change.Considering the current healthcare challenges that we face today, the goal of achieving better health outcomes is a moving target that requires daring and adaptable solutions. HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support:Breakthrough Technologies: Paradigm shifting technologies that will change how we approach the diagnosis, treatment, and impact of diseases and conditions. Novel approaches to improve maternal and fetal medicine, decrease maternal morbidity and mortality during birth, and the post-partum period. Efforts should include new technology to monitor, detect, and/or treat maternal and/or fetal complications with less invasive and traumatic methods. Foundational advances in genetic, epigenetic, cellular, tissue, and organ replacement therapies that enable personalized medical interventions at scale in a manner that is accessible, cost-effective, and designed to impact the communities of greatest need. Interventions that target and reverse disease pathogenesis and/or enhance plasticity to address diseases of the nervous, neuromuscular, skeletal, lymphatic, cardiovascular, and other organ systems. Novel approaches to diagnose and treat diseases of the lymphatic system, particularly rare diseases, with a focus on the effects of genetic expression in the lymphatic system and/or models demonstrating the relationship between lymphatic dysfunction and health and disease.Transformative Tools: Novel, agile solutions that will move from bench to bedside quickly, facilitating revolutionary advances in medical care. Development of tools that counter idiosyncratic, off-target, or chronic effects of medicines that are commonly used or that are being used experimentally to treat or prevent disease. Development of bionics to restore sight, hearing, taste, or smell. Site-selective neuromodulation to regulate specific physiological functions and treat chronic health conditions such as inflammation, pain, and metabolic or endocrine disorders. Synthetic biology approaches to diagnosing, treating, and/or curing a multitude of diseases. Novel physics and/or chemistry-based approaches to improve imaging that reduces cost, increases availability, expands capability, improves resolution, reduces exposure to radiation, and accommodates pediatric patient populations. Integrated sensing and delivery devices for treating and diagnosing chronic health conditions, including mental health conditions or substance use disorders. Miniaturization of complex hardware to enable broader access to pediatric and other patient populations, as well as portability, such as diagnostic, treatment, imaging, or other devices.Platform Systems: Adaptable, multi-application systems and technologies that are reconfigurable for a wide variety of clinical needs Novel molecular platform approaches, including the modulation of host systems, delivery to targets with spatial and temporal precision, and mitigation of off-target effects to accelerate interventions that dramatically improve health outcomes. New approaches to accelerate and routinize mammalian and microbial cellular engineering to enable next generation therapeutic applications, develop multiscale interventions, and automate hypothesis generation and discovery to expand those applications to disease states in which cellular therapies have not traditionally been employed. Innovative approaches at the intersection of artificial intelligence, high performance computing (including quantum computing) and biological systems, including enabling de novo design of biomolecules with entirely new phenotypes.Other high-quality submissions that propose revolutionary technologies that meet the goals of HSF will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy changes, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.